UK markets close in 6 hours 38 minutes
  • FTSE 100

    7,075.12
    +12.83 (+0.18%)
     
  • FTSE 250

    22,529.61
    +72.53 (+0.32%)
     
  • AIM

    1,219.49
    -1.52 (-0.12%)
     
  • GBP/EUR

    1.1660
    -0.0028 (-0.24%)
     
  • GBP/USD

    1.3875
    -0.0058 (-0.41%)
     
  • BTC-GBP

    22,800.95
    -1,174.74 (-4.90%)
     
  • CMC Crypto 200

    756.58
    -93.77 (-11.03%)
     
  • S&P 500

    4,224.79
    +58.34 (+1.40%)
     
  • DOW

    33,876.97
    +586.89 (+1.76%)
     
  • CRUDE OIL

    73.08
    -0.58 (-0.79%)
     
  • GOLD FUTURES

    1,778.00
    -4.90 (-0.27%)
     
  • NIKKEI 225

    28,884.13
    +873.20 (+3.12%)
     
  • HANG SENG

    28,309.76
    -179.24 (-0.63%)
     
  • DAX

    15,526.52
    -76.72 (-0.49%)
     
  • CAC 40

    6,586.26
    -16.28 (-0.25%)
     

What Really Mattered With Editas Medicine's Q1 Update

·3-min read
What Really Mattered With Editas Medicine's Q1 Update
  • Oops!
    Something went wrong.
    Please try again later.

Editas Medicine (NASDAQ: EDIT) entered 2021 with tremendous momentum. The company announced a Q1 net loss of $56.7 million, or $0.86 per share, based on generally accepted accounting principles (GAAP). In the prior-year period, Editas posted a GAAP net loss of $37.7 million, or $0.69 per share.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting